Nektar Product NKTR-358 Shows Promise in Autoimmune and Chronic Inflammatory Conditions
June 13, 2019
3
Nektar Announced Results for NKTR-358 During an oral session at the Annual European Congress of Rheumatology (EULAR) 2019, in Madrid, Nektar Therapeutics (NKTR) announced results of the first-in-human Phase 1a study evaluating single-ascending doses of NKTR-358 for the treatment of autoimmune and other chronic inflammatory conditions. The . . . This content is for paid subscribers. Please click here to subscribe or here to log in.